DoD Tick-Borne Disease, Therapeutic/Diagnostic Research Award
ID: 353719Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353719
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Tick-Borne Disease Therapeutic/Diagnostic Research Award, aimed at supporting innovative research projects focused on therapeutic and diagnostic advancements for tick-borne diseases, particularly Lyme disease. Applicants are encouraged to propose studies that demonstrate feasibility and have translational potential to improve patient care for military personnel, veterans, and the general public. The program has a total funding pool of $2,656,000, with a maximum budget of $830,000 per project over three years, and requires a pre-application submission by June 26, 2024, followed by a full application due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524TBDRPTDRA_GG.pdf
    The DOD FY24 Tick-Borne Disease Therapeutic/Diagnostic Research Award seeks innovative projects to combat tick-borne diseases, particularly Lyme disease, within a funding pool of $7 million. Interested applicants must submit a pre-application by June 26, 2024, and, if invited, a full application by October 3, 2024. The program focuses on therapeutic evaluation for treatment and advancements in diagnostic methods, with the aim of improving patient care for military personnel and the general public affected by these diseases. Grant recipients are encouraged to collaborate with experienced tick-borne disease researchers and integrate their work with DOD and VA programs. Applications involving human subjects are permitted but must adhere to specific safety and ethical guidelines, while clinical trials are excluded from funding. The maximum budget for any project is $830,000 over a three-year period, and each project must demonstrate its potential long-term benefits for public health and military relevance. The submission process is rigorous, requiring detailed documentation and adherence to guidelines, highlighting the program’s commitment to address critical health challenges posed by tick-borne diseases effectively.
    Similar Opportunities
    Funding Opportunity Title:Deployed Warfighter Protection (DWFP) Program for the Protection of Deployed Military Personnel from Threats Posed by Arthropod Disease Vectors
    Department of Defense
    The Department of Defense is offering a funding opportunity through the Fiscal Year 2025 Deployed Warfighter Protection (DWFP) Program, aimed at safeguarding military personnel from threats posed by arthropod disease vectors. The program seeks innovative research proposals focused on developing new insecticides, personal protection technologies, and improved vector control strategies, with applications required to address specific research areas such as bite prevention, vector control, and diagnostics. This initiative is crucial for enhancing health protection in military operations and has a total estimated funding of $5 million, with individual awards capped at $975,000 over three years. Interested applicants must submit a pre-application by October 4, 2024, and a full application by January 28, 2025; for further inquiries, contact Scott I. Hoffman at scott.i.hoffman2.civ@army.mil or call 1-520-671-1470.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Airman Readiness Medical Research (ARMR) Hybrid BAA
    Air Force -- Research Lab
    The Air Force Research Laboratory (AFRL) is soliciting proposals for the Airman Readiness Medical Research (ARMR) program through a Hybrid Broad Agency Announcement (BAA) designated FA8650-20-S-6008. The primary objectives of this initiative are to conduct medical research aimed at optimizing the health and performance of Airmen, focusing on ensuring medical availability and understanding the effects of various operational environments on Airman well-being. This program is critical for enhancing the operational readiness of military personnel, particularly in high-demand mission scenarios, with key research areas including aeromedical evacuation, cognitive performance, and exposure health. The total funding available for this program is estimated at $480 million, with individual awards ranging from $50,000 to $49 million. Interested parties are encouraged to submit white papers by May 1, 2025, and can direct inquiries to Amber A. Taylor at amber.taylor.9@us.af.mil.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    US Army Combat Capabilities Development Command Broad Agency Announcement
    ACC APG - Natick
    The US Army Combat Capabilities Development Command (CCDC) is inviting proposals through its Broad Agency Announcement (BAA) for research and development funding, managed by the ACC APG - Natick. This opportunity allows unrestricted applicants to submit white papers and proposals for grants and assistance agreements, focusing on various areas of interest outlined in the BAA solicitation document. The initiative is crucial for advancing the capabilities of the Army, with an expected 50 awards to be made. Interested parties should note that the submission deadline is February 28, 2025, and can reach out to Shawn P. Haubner at shawn.p.haubner.civ@mail.mil or by phone at 508-206-2067 for further information.
    International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" aimed at supporting research on infectious diseases in resource-constrained countries. This initiative encourages applications from organizations based in low- and lower-middle-income economies, as classified by the World Bank, and seeks innovative proposals addressing diseases such as HIV/AIDS, tuberculosis, and malaria, with a focus on enhancing local scientific capacity. The total funding available for fiscal year 2024 is approximately $1,360,000, with individual project budgets capped at $125,000 per year for a maximum of five years. Interested applicants can find more information and submission guidelines at the NIH website, with applications accepted until August 1, 2025.
    Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities
    Centers for Disease Control - NCEZID
    The Centers for Disease Control and Prevention (CDC) is forecasting a federal grant opportunity aimed at reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. This initiative, structured as a cooperative agreement, focuses on three key components: enhancing healthcare provider knowledge and practices regarding Chagas disease, expanding public health surveillance for soil-transmitted helminths, and addressing other significant parasitic diseases of domestic concern. With an estimated total program funding of $10 million and an award ceiling of $1 million, the CDC anticipates making approximately seven awards, with applications due by May 2, 2025. Interested applicants can reach out to Emily Dodd at 404-639-3753 or via email at iog2@cdc.gov for further information.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R21 Clinical Trial Not Allowed), aimed at advancing research in the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between microorganisms, tumors, and the immune system, focusing on their potential to develop innovative strategies for cancer imaging and therapeutics, particularly for solid tumors and oral cancers. The program supports exploratory and developmental research with a maximum budget of $275,000 over two years, encouraging multidisciplinary collaboration to address significant challenges in cancer therapy. Applications are due by May 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.